Shandong Jincheng Pharmaceutical Group (300233.SZ) has obtained the drug registration certificate for the Metronidazole Chloride Sodium Injection.

Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its controlling subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. (referred to as "Jincheng Jinsu"), has received the drug registration certificate for metronidazole and chlorhexidine gluconate injection issued by the National Medical Products Administration. The announcement shows that metronidazole is a nitroimidazole antibacterial drug. By replacing the unstable chlorine ion in ornidazole with a more stable imidazole ring, the structure becomes more stable and the incidence of adverse reactions is lower. This product is suitable for the following adult (18 years old) infections caused by sensitive bacteria: 1. Pelvic inflammatory disease caused by bacteria including group B streptococcus, fragile pseudomonas, veillonella, gardnerella, etc. (including endometritis, salpingitis, tubo-ovarian abscess, pelvic peritonitis, etc.); 2. Suppurative appendicitis and gangrenous appendicitis caused by bacteria including pseudomonas species (fragile pseudomonas, oval/ polymorphic pseudomonas, single-shape pseudomonas, ordinary pseudomonas, pseudomonas species), clostridium species (gas-producing clostridium, double-enzyme clostridium, propionic clostridium, and other clostridium), bacillus species (nucleated bacillus, variable bacillus), anaerobic cocci (group B streptococcus, veillonella); 3. Mixed infections of pelvic inflammatory disease and appendicitis caused by anaerobic and aerobic bacteria.